Aurora Cannabis vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Aurora Cannabis Inc (ACB)

Q3 20268 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

September 20268 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

Latest8 Aug – 5 Oct 2026

▲2

Curaleaf's hostile bid for Aurora dominates the period

International medical cannabis keeps growing Aurora's international medical revenue rose 17% to C$43.3 million, with 64% of sales now outside Canada and a 58% gross margin. This high-margin growth is the core reason the business is worth more, even as total revenue fell on a Canadian reimbursement cut.
Shows the fundamental business driver behind Aurora's value, separate from the takeover noise.
Curaleaf's takeover bid lifts the shares Curaleaf launched a hostile bid worth $4 per Aurora share, a 45% premium, later saying it intends to raise it to $5. The offer gives shareholders a concrete cash-and-stock alternative and has pushed ACB sharply higher as investors weigh the deal.
The bid is the single biggest force moving ACB's price this period.
Aurora resists, arguing it is stronger alone Aurora urged shareholders to take no action, highlighting its $149 million cash and no debt versus Curaleaf's roughly $1 billion in debt. The fight keeps a floor under the stock but leaves the outcome uncertain until the bid expires December 4.
Explains the counterweight to the bid and why the situation is not a simple win for ACB holders.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.